

Final agenda, SafeBoosC investigator meeting January 2020

Session 1, 'Up and running' (2 hours)

- Welcome – Gorm Greisen
- 'Up and running' with national coordinators – a status on trial preparations and randomisation in each country
- Status on the trial – Mathias Lühr Hansen
- What else is going on, out there?
 - COSGOD – Gerhard Pichler
 - NEO-CIRC – Adelina Pellicer
 - Cerebral near-infrared spectroscopy monitoring (NIRS) to prevent brain injury and/or death in children and adults: a meta-analysis – Mathias Lühr Hansen
 - Additional NIRS studies – Gorm Greisen

Session 2, 'Round-up from yesterday' and 'Optimizing the intervention in the experimental group' (3 hours)

- Good morning and welcome – Gorm Greisen
- Regional round-table discussions on yesterday's presentations
- SafeBoosC web-based training and certification program – room for improvement? – Marie Rasmussen
 - How to create a user, managing the training platform and modules
 - Group training in NIRS- and treatment guideline module
 - Discussion on points for improvement
- Cerebral NIRS monitoring – Simon Hyttel-Sørensen
- SafeBoosC Treatment guideline – Adelina Pellicer
- Experiences with treatment guided by cerebral oxygenation monitoring in SafeBoosC III
 - Cases from the SafeBoosC Trial - Kosmas Sarafidis, Jan Sirc, Salvador Piris, Miguel Alsina
 - Round-table discussion on experience with treatment and NIRS monitoring
 - Sum-up in plenum

Session 3, 'Optimizing SafeBoosC III as a trial' – 3 hours

- Weaknesses in the SafeBoosC III trial – Gorm greisen
- Landscape of large-scale neonatal trials – Eugene Dempsey
- How to set-up SafeBoosC III in your hospital, experience from Copenhagen – Gitte Hahn
- Blinding the diagnosis of brain injury and data entry
 - Why blinding is so important – Janus Christian Jakobsen
 - Examples and experience on blinding procedures in SafeBoosC III - Ebru Ergenekon, Luis Arruza, Miguel Alsina, Cornelia Hagmann
- Ancillary studies
 - Polish ancillary study – Tomasz Szczapa
 - US ancillary study – Mathias Lühr Hansen
 - Follow up study – Mathias Lühr Hansen
 - Others?

